Table 2—

The effect of baseline strata on the relative risk of developing type 2 diabetes over 4 years in patients, irrespective of treatment

VariableHazard ratio95% CIP
Treatment group: orlistat versus placebo0.63(0.46–0.87)0.0052
Glucose tolerance: impaired versus normal10.60(7.30–15.40)<0.0001
Sex: male versus female1.41(1.02–1.96)0.0390
Age (years): >44* vs. ≤441.44(1.02–2.04)0.0383
BMI (kg/m2): ≥37 vs. <37*1.36(0.97–1.91)0.0726